Table 1.
Characteristics of included studies for the meta-analyses.
| Study | Country | Enrolled patients | Intervention | ICI | Neoadjuvant cycle | NCT or ChiCTR identifier | |||
|---|---|---|---|---|---|---|---|---|---|
| Sample size, No. | Male, No. (%) | Clinical stage | Histological type | ||||||
| Bingjiang Huang et al, 2021 (26) | China | 54 | 51 (94.4%) |
cT2-4N1-3M0 | ESCC | nICT vs nCT | pembrolizumab | 2 | ChiCTR2000035079 |
| Zhinuan Hong et al, 2022 (27) | China | 87 | 68 (78.2%) |
cT1N1-3M0 or cT2-4aN 0-3M0 | ESCC | nICT vs nCRT | sintilimab pembrolizumab toripalimab camrelizumab |
2-4 | NR |
| Shaowu Jing et al, 2022 (28) | China | 94 | 63 (67.0%) |
cT3-4aN0-2M0 | ESCC | nICT vs nCT | sintilimab pembrolizumab toripalimab camrelizumab |
1-3 | NR |
| Smita Sihag et al, 2021 (29) | USA | 168 | 146 (86.9%) |
NR | EAC | nICRT vs nCRT | durvalumab | 2 | NCT02962063 |
| Tom van don Ende et al, 2021 (30) | Netherlands | 80 | 71 (88.7%) |
NR | EAC | nICRT vs nCRT | atezolizumab | 5 | NCT03087864 |
| Zhinuan Hong et al, 2021 (31) | China | 122 | 101 (82.8%) |
cT1N1-3 M0 or cT2-4aN 0-3M0 | ESCC | nICT vs nCT | sintilimab pembrolizumab camrelizumab |
2-4 | ChiCTR2100045659 |
| Jiahan Cheng et al, 2022 (32) | China | 149 | 123 (82.6%) |
cT2-4N1-3M0 | ESCC | nICT vs nCRT | sintilimab pembrolizumab camrelizumab toripalimab tislelizumab |
2-4 | NR |
| Xuewei Ding et al, 2023 (33) | China | 47 | NR | NR | EAC | nICT vs nCT | sintilimab | 3 | NCT04982939 |
ESCC, esophageal squamous cell carcinoma; EAC, esophageal adenocarcinoma; nICT, neoadjuvant immune checkpoint inhibitor in combination with chemotherapy; nICRT, neoadjuvant immune checkpoint inhibitor in combination with chemoradiotherapy; nCT, neoadjuvant chemotherapy; nCRT, neoadjuvant chemoradiotherapy; NR, not reported.